IOVANCE BIOTHERAPEUTICS, INC. IOVA

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing derived Nasdaq

We are a commercial-stage biopharmaceutical company pioneering a transformational approach to treating cancer. Our mission is to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte, or TIL, cell therapies for patients with solid tumor cancers. TIL cell therapies harness the individual immune system's ability to recognize and destroy diverse cancer cells that are unique to each patient. These individualized therapies are manufactured using centralized, scalable, and proprietary manufacturing processes which rejuvenate and multiply each patient's polyclonal T cells into the billions.

Iovance was founded to build upon the promise of TIL cell therapy initially developed at academic research centers, including the National Cancer Institute, or the NCI. Our multi-center trials, scalable manufacturing, regulatory approvals and commercial infrastructure have transformed TIL cell therapy from a research product available to only a small number of patients, into a commercially viable treatment that is accessible for thousands of cancer patients.

Last close 14.09 2026-10-23
Market cap $6.38B 2026-06-30 share count
52-week range 1.76 - 15.37

Valuation FY2025 figures against the last close

P/S24.2x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-1.09

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $263.5M$164.1M$1.2M————$0$0$0
Cost of revenue $173.2M$93.2M$1.0M———————
Gross profit $90.3M$70.8M$156.0K———————
R&D $300.3M$276.2M$333.2M$294.8M$259.0M$201.7M$166.0M$99.8M$71.6M$26.9M
SG&A $152.3M$152.3M$106.1M$104.1M$83.7M$60.2M$40.8M$28.4M$21.3M$26.7M
Total operating expenses $666.9M$559.3M$461.7M$398.9M$342.7M$261.9M$206.9M$128.3M$92.9M$53.6M
Operating income -$403.4M-$395.3M-$460.6M-$398.9M-$342.7M-$261.9M-$206.9M-$128.3M-$92.9M-$53.6M
Pre-tax income -$393.0M-$375.0M-$447.5M-$395.9M-$342.3M-$259.6M-$197.6M-$123.6M-$92.1M-$52.9M
Income tax $2.1M$2.8M$3.5M$0$0$0$0$0$0$0
Net income -$391.0M-$372.2M-$444.0M-$395.9M-$342.3M-$259.6M-$197.6M-$123.6M-$92.1M-$52.9M
EPS, basic -1.09-1.28-1.89-2.49-2.23-1.88-1.59———
EPS, diluted -1.09-1.28-1.89-2.49-2.23-1.88-1.59-1.27-1.41-1.85
Shares, diluted (wtd. avg.) 357,345289,877235,131159,259153,406138,301124,336———

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $163.1M$115.7M$114.9M$238.2M$84.3M$72.9M$19.4M$82.2M$145.4M$106.7M
Short-term investments $133.9M$208.1M$165.0M$240.1M$426.2M$562.1M$293.1M$386.4M——
Receivables $82.4M$69.3M$151.0K———————
Inventory $51.7M$51.5M$10.4M———————
Total current assets $442.7M$457.0M$307.8M$479.1M$508.0M$636.1M$316.5M$475.4M$149.3M$169.5M
Property, plant and equipment $131.1M$109.1M$114.0M$105.2M$100.9M$59.2M$8.5M$2.7M$2.5M$2.4M
Other intangibles $279.3M$282.4M$229.3M———————
Total assets $913.2M$910.4M$780.4M$664.0M$777.3M$768.5M$344.7M$480.8M$155.4M$171.9M
Accounts payable $22.2M$27.5M$33.1M$26.6M$27.4M$13.5M$15.6M$2.7M$1.2M$863.0K
Total current liabilities $138.4M$122.3M$110.3M$91.5M$89.2M$54.9M$39.1M$14.4M$9.6M$5.0M
Total liabilities $214.6M$200.0M$195.7M$164.3M$155.7M$112.0M$45.7M$14.6M$9.9M—
Retained earnings -$2.78B-$2.38B-$2.01B-$1.57B-$1.17B-$830.2M-$570.6M-$372.8M-$249.2M-$157.1M
Total equity $698.6M$710.4M$584.6M$499.6M$621.7M$656.5M$299.0M$466.2M$145.5M$166.9M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$302.4M-$353.0M-$361.8M-$292.8M-$227.9M-$205.1M-$158.9M-$101.2M-$78.7M-$32.7M
Depreciation and amortisation $12.9M$11.3M$11.6M$9.3M$3.1M$1.1M$1.2M$956.0K$952.0K$1.0M
Stock-based compensation $61.6M$109.6M$62.6M$84.0M$69.8M$40.9M$24.3M$20.0M$12.0M$18.9M
Capital expenditure $33.8M$11.1M$22.3M$20.4M$37.6M$46.8M$6.9M$1.2M$1.0M$1.5M
Investing cash flow $47.5M-$96.4M-$155.2M$256.5M$132.0K-$317.9M$90.0M-$386.3M$58.7M$8.9M
Financing cash flow $300.8M$390.7M$463.0M$190.2M$239.3M$576.4M$6.1M$424.3M$58.7M$96.9M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-050458.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -600M -400M -200M 0 200M 400M Revenue, FY2016: 0 Net income, FY2016: -52.9M Revenue, FY2017: 0 Net income, FY2017: -92.1M Revenue, FY2018: 0 Net income, FY2018: -123.6M Net income, FY2019: -197.6M Net income, FY2020: -259.6M Net income, FY2021: -342.3M Net income, FY2022: -395.9M Revenue, FY2023: 1.2M Gross profit, FY2023: 156K Net income, FY2023: -444M Revenue, FY2024: 164.1M Gross profit, FY2024: 70.8M Net income, FY2024: -372.2M Revenue, FY2025: 263.5M Gross profit, FY2025: 90.3M Net income, FY2025: -391M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $0 $0 $0 — — — — $1.2M $164.1M $263.5M
Gross profit — — — — — — — $156.0K $70.8M $90.3M
Net income -$52.9M -$92.1M -$123.6M -$197.6M -$259.6M -$342.3M -$395.9M -$444.0M -$372.2M -$391.0M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Other event Item 8.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Other event Item 8.01
  • Results announced Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Other event Item 8.01
  • Other event Item 8.01
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $237.48B 30.9x 10.0%
GILD GILEAD SCIENCES, INC. $193.48B 23.0x 2.4%
MRNA Moderna, Inc. $79.89B — -39.9%
RVMD Revolution Medicines, Inc. $40.08B — —
BIIB BIOGEN INC. $37.01B 28.5x 2.2%
EXEL EXELIXIS, INC. $15.99B 23.2x 7.0%
NBIX NEUROCRINE BIOSCIENCES INC $14.51B 30.6x 21.4%
HALO HALOZYME THERAPEUTICS, INC. $14.26B 49.1x 37.6%